Hostname: page-component-74656f9884-6grmk Total loading time: 0 Render date: 2026-11-06T07:54:31.001Z Has data issue: false hasContentIssue false

Luria's three-step test: what is it and what does it tell us?

Published online by Cambridge University Press:  04 May 2011

Myron F. Weiner*
Affiliation:
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas, USA Department of Neurology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Linda S. Hynan
Affiliation:
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas, USA Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Heidi Rossetti
Affiliation:
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas, USA Department of Psychiatry and Neurobehavioral Sciences, University of Virginia Health System, Charlottesville, Virginia, USA
Jed Falkowski
Affiliation:
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas, USA
*
Correspondence should be addressed to: Myron F. Weiner, MD, 5323 Harry Hines Blvd., Dallas, Texas 75390–9129, USA. Phone: +1 214-648-9353; Fax: +1 214-648-2031. Email: myron.weiner@utsouthwestern.edu.

Abstract

Background: The purpose of this study is to determine if the three-step Luria test is useful for differentiating between cognitive disorders.

Methods: A retrospective record review of performance on the three-step Luria test was conducted on 383 participants from a university-based dementia clinic. The participants ranged in their diagnosis from frontotemporal dementia (FTD; n = 43), Alzheimer disease (AD; n = 153), mild cognitive impairment (MCI; n = 56), and normal controls (NC; n = 131). Performance of the Luria test was graded as normal or abnormal.

Results: An abnormal test occurred in 2.3% of NC, 21.4% of MCI, 69.8% of FTD, and 54.9% of AD subjects. The frequency of abnormal tests in all diagnostic groups increased with functional impairment as assessed by the Clinical Dementia Rating scale (CDR). When CDR = 3 (severe), 100% of the FTD and 72.2% of the AD subjects had abnormal Luria tests.

Conclusions: The three-step Luria test distinguished NC and persons with MCI from FTD and AD, but did not distinguish FTD from AD subjects.

Information

Type
Research Article
Copyright
Copyright © International Psychogeriatric Association 2011
Figure 0

Table 1. Age, education and MMSE by diagnostic group

Figure 1

Table 2. Performance on Luria test by age, education, and MMSE

Figure 2

Table 3. Impaired Luria test by diagnosis group and Clinical Dementia Rating score for measures recorded at initial Luria test visit

Figure 3

Table 4. The number (%) of patients with abnormal Luria test results by disease progression, diagnosis group and initial CDR global scores